200 related articles for article (PubMed ID: 8965179)
1. Iodine-123-iodobenzamide binding in parkinsonism: reduction by dopamine agonists but not L-Dopa.
Schwarz J; Oertel WH; Tatsch K
J Nucl Med; 1996 Jul; 37(7):1112-5. PubMed ID: 8965179
[TBL] [Abstract][Full Text] [Related]
2. [123]IBZM binding predicts dopaminergic responsiveness in patients with parkinsonism and previous dopaminomimetic therapy.
Schwarz J; Tatsch K; Gasser T; Arnold G; Oertel WH
Mov Disord; 1997 Nov; 12(6):898-902. PubMed ID: 9399212
[TBL] [Abstract][Full Text] [Related]
3. 123I-IBZM binding compared with long-term clinical follow up in patients with de novo parkinsonism.
Schwarz J; Tatsch K; Gasser T; Arnold G; Pogarell O; Künig G; Oertel WH
Mov Disord; 1998 Jan; 13(1):16-9. PubMed ID: 9452320
[TBL] [Abstract][Full Text] [Related]
4. [Dopamine (D2) receptor SPECT with 123I-iodobenzamide (IBZM) in diagnosis of Parkinson syndrome].
Reiche W; Grundmann M; Huber G
Radiologe; 1995 Nov; 35(11):838-43. PubMed ID: 8657887
[TBL] [Abstract][Full Text] [Related]
5. 123I-iodobenzamide-SPECT in 83 patients with de novo parkinsonism.
Schwarz J; Tatsch K; Arnold G; Ott M; Trenkwalder C; Kirsch CM; Oertel WH
Neurology; 1993 Dec; 43(12 Suppl 6):S17-20. PubMed ID: 8264906
[TBL] [Abstract][Full Text] [Related]
6. 123I-iodobenzamide-SPECT predicts dopaminergic responsiveness in patients with de novo parkinsonism.
Schwarz J; Tatsch K; Arnold G; Gasser T; Trenkwalder C; Kirsch CM; Oertel WH
Neurology; 1992 Mar; 42(3 Pt 1):556-61. PubMed ID: 1549216
[TBL] [Abstract][Full Text] [Related]
7. [Cerebral SPECT with iodine-123 IBZM in patients with extrapyramidal system disorders: the evaluation of its sensitivity in therapy with dopaminergic drugs].
Hierholzer J; Castelli L; Cordes M; Schelosky L; Poewe W; Felix R
Radiol Med; 1996 Mar; 91(3):207-10. PubMed ID: 8628932
[TBL] [Abstract][Full Text] [Related]
8. Alterations of striatal dopamine D2 receptors contribute to deteriorated response to L-dopa in Parkinson's disease: a [123I]-IBZM SPET study.
Pizzolato G; Chierichetti F; Rossato A; Cagnin A; Fabbri M; Dam M; Ferlin G; Battistin L
J Neural Transm Suppl; 1995; 45():113-22. PubMed ID: 8748616
[TBL] [Abstract][Full Text] [Related]
9. Dopamine D2 receptor imaging with SPECT: studies in different neuropsychiatric disorders.
Brücke T; Podreka I; Angelberger P; Wenger S; Topitz A; Küfferle B; Müller C; Deecke L
J Cereb Blood Flow Metab; 1991 Mar; 11(2):220-8. PubMed ID: 1671782
[TBL] [Abstract][Full Text] [Related]
10. IBZM-SPECT as predictor for dopamimetic responsiveness of patients with de novo parkinsonian syndrome.
Oertel WH; Schwarz J; Tatsch K; Arnold G; Gasser T; Kirsch CM
Adv Neurol; 1993; 60():519-24. PubMed ID: 8420182
[TBL] [Abstract][Full Text] [Related]
11. [The differential diagnosis of Parkinson diseases--123I-IBZM-SPECT vs. the apomorphine test].
Hierholzer J; Cordes M; Schelosky L; Sander B; Böck JC; David I; Horowski R; Poewe W
Rofo; 1993 Jul; 159(1):86-90. PubMed ID: 8334264
[TBL] [Abstract][Full Text] [Related]
12. [The determination of cerebral dopamine (D2) receptor density by using 123I-IBZM-SPECT in Parkinson disease patients].
Hierholzer J; Cordes M; Schelosky L; Barzen G; Poewe W; Henkes H; Keske U; Horowski R; Felix R
Rofo; 1992 Oct; 157(4):390-8. PubMed ID: 1391843
[TBL] [Abstract][Full Text] [Related]
13. Comparison of 123I-IBZM SPECT and 11C-raclopride PET findings in patients with parkinsonism.
Schwarz J; Antonini A; Tatsch K; Kirsch CM; Oertel WH; Leenders KL
Nucl Med Commun; 1994 Oct; 15(10):806-13. PubMed ID: 7838444
[TBL] [Abstract][Full Text] [Related]
14. Continuous intravenous infusion of iodine-123-IBZM for SPECT determination of human brain dopamine receptor occupancy by antipsychotic agent RWJ-37796.
Seibyl JP; Zea-Ponce Y; Brenner L; Baldwin RM; Krystal JH; Offord SJ; Mochoviak S; Charney DS; Hoffer PB; Innis RB
J Nucl Med; 1996 Jan; 37(1):11-5. PubMed ID: 8543979
[TBL] [Abstract][Full Text] [Related]
15. Initial experience with SPECT examinations using [123I]IBZM as a D2-dopamine receptor antagonist in Parkinson's disease.
Cordes M; Henkes H; Laudahn D; Bräu H; Kramp W; Girke W; Hierholzer J; Eichstädt H; Felix R
Eur J Radiol; 1991; 12(3):182-6. PubMed ID: 1830273
[TBL] [Abstract][Full Text] [Related]
16. Dopamine receptor SPET imaging in Parkinson's disease: a [123I]-IBZM and [99mTc]-HM-PAO study.
Pizzolato G; Chierichetti F; Rossato A; Briani C; Dam M; Borsato N; Saitta B; Zanco P; Ferlin G; Battistin L
Eur Neurol; 1993; 33(2):143-8. PubMed ID: 8467821
[TBL] [Abstract][Full Text] [Related]
17. Striatal dopamine D2 receptor alterations and response to L-DOPA in Parkinson's disease. A [123I]IBZM SPET study.
Pizzolato G; Cagnin A; Rossato A; Chierichetti F; Fabbri M; Dam M; Ferlin G; Battistin L
Adv Neurol; 1996; 69():467-73. PubMed ID: 8615167
[No Abstract] [Full Text] [Related]
18. Correlation of clinical response in apomorphine test with D2-receptor status as demonstrated by 123I IBZM-SPECT.
Schelosky L; Hierholzer J; Wissel J; Cordes M; Poewe W
Mov Disord; 1993 Oct; 8(4):453-8. PubMed ID: 8232354
[TBL] [Abstract][Full Text] [Related]
19. 123I-IBZM SPECT: reconstruction methodology and results in parkinsonism and dystonia.
Berding G; Gratz KF; Kolbe H; Meyer GJ; Dengler R; Knoop BO; Hundeshagen H
Nuklearmedizin; 1994 Oct; 33(5):194-9. PubMed ID: 7997377
[TBL] [Abstract][Full Text] [Related]
20. 123I-beta-CIT and 123I-IBZM-SPECT scanning in levodopa-naive Parkinson's disease.
Wenning GK; Donnemiller E; Granata R; Riccabona G; Poewe W
Mov Disord; 1998 May; 13(3):438-45. PubMed ID: 9613734
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
